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Abstract: The oncogenic phosphatidylinositol 3-kinase-AKT-mammlian target of rapamycin pathway (PI3K-AKT-
mTOR) pathway is known to be activated in uterine smooth muscle tumors, and Stathmin 1 (STMN1) expression 
has been identified as a marker of PI3K-AKT-mTOR pathway activation. We hypothesized that STMN1 may have 
some diagnostic utility and explored how well STMN1 expression correlated with histologic classifications of uterine 
smooth muscle tumors into benign and malignant groupings. 84 smooth muscle tumors were assessed for STMN1 
expression by immunohistochemistry. These included spindle cell leiomyosarcoma (n = 32), conventional spindle 
cell leiomyomas (n = 30), atypical (symplastic) leiomyoma (n = 5), cellular leiomyoma (n = 7), smooth muscle tumor 
of uncertain malignant potential (n = 4), mitotically active leiomyomas (n = 2), benign metastasizing leiomyoma (n = 
3), and cotyledonoid dissecting leiomyoma (n = 1). All spindle cell leiomyosarcomas were positive (32/32 positive; 
100%) as compared with conventional leiomyomata (11/30; 37%) (P < 0.0001). The average immunohistochemical 
score (0-12+, reflective of intensity and extent) for leiomyosarcomas was 8.7 (± 1.43) whereas the conventional 
leiomyomata average score was 1.6 (± 1.07) (P < 0.0001). This difference in scores was reflected in the patterns 
of expression: leiomyosarcomas were predominantly strongly and diffusely positive whereas leiomyomata were 
predominantly weakly, albeit diffusely positive when expression was present. The sensitivity of STMN1 expression 
for leiomyosarcomas was 100%. However, the specificity was found to be only 55% (CI = 43-68%). The negative 
and positive predictive values for leiomyosarcomas were 100% and 52% respectively. The odds ratio (OR) for any 
STMN1 expression in predicting a spindle cell leiomyosarcoma diagnosis from this dataset was highly significant (OR 
= 144, P = 0.0006). Thirteen non-smooth muscle tumors that involved the uterus all showed at least focal STMN1 
immunoreactivity. In summary, STMN1 is a highly sensitive marker for leiomyosarcoma but is suboptimally specific 
for diagnostic purposes. The 100% negative predictive value for leiomyosarcoma may offer some diagnostic utility in 
a small sample, since the absence of STMN1 immunoreactivity in a putative leiomyosarcoma is a strong argument 
against this diagnostic possibility.
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Introduction
Uterine leiomyosarcomas are rare, represent-
ing approximately 1% of uterine malignancies, 
40% of all uterine sarcomas, and with an annu-
al incidence of approximately 0.64 per 100,000 
women [1-5]. Although these are rare tumors, 
leiomyosarcomas are clinically aggressive, with 
5-year survival rates of between 25-75% [3, 
6-11]. In general, pathologic classifications of 
smooth muscle tumors show a strong correla-
tion with patient outcomes. However, it has long 
been recognized that the diagnosis of some 
smooth muscle tumors can be problematic, 
Stathmin expression in uterine smooth muscle tumors
2796 Int J Clin Exp Pathol 2015;8(3):2795-2801
including tumors displaying extrauterine dis-
ease but bland morphology and favorable 
patient outcomes, tumors displaying bland his-
tology and clinical aggressiveness, and other 
tumors that in general, show a dissonance 
between pathologic features and patient out-
comes [11-15]. Accordingly, immunohistoch- 
emical (IHC) markers that may assist in differ-
entiating between a leiomyosarcoma and a 
uterine leiomyoma will be clinically helpful. A 
variety of such markers, including p21, p27, 
p53, p16, IMP3, pan-Akt, Ki-67, and fascin 
have previously been evaluated [10, 16-26]. 
Although each has shown varying degrees of 
efficacy for this purpose, they generally lack the 
specificity to be deployed in isolation.
Stathmin 1 (STMN1), also known as oncopro-
tein 18, is a cytoplasmic phosphoprotein that is 
involved in regulating the dynamics of mitotic 
and interphase microtubules. As such, dysregu-
lation of stathmin expression may result in 
pathway (PI3K-AKT-mTOR) pathway [36-40]. 
This pathway is known to be highly activated in 
both uterine and extrauterine leiomyosarcoma 
[27-32]. Accordingly, we hypothesized that ST- 
MN1 has some diagnostic utility in classifying 
uterine smooth muscle tumors regarding their 
malignant potential and explored how well 
STMN1 expression correlated with histologic 
classifications of uterine smooth muscle tum- 
ors into benign and malignant groupings. In 
summary, STMN1 is a highly sensitive marker 
for leiomyosarcoma but is suboptimally specific 
for diagnostic purposes. The 100% negative 
predictive value for leiomyosarcoma may offer 
some diagnostic utility in a small sample, since 
the absence of STMN1 immunoreactivity in a 
putative leiomyosarcoma is a strong argument 
against the diagnosis.
Materials and methods
Case selection
84 smooth muscle tumors that had previously 
been classified based on World Health Org- 
anization criteria [41], were selected from the 
authors’ files. The cases included spindle cell 
leiomyosarcoma (n = 32), conventional spindle 
cell leiomyomas (n = 30), atypical (symplastic) 
leiomyoma (n = 5), cellular leiomyoma (n = 7), 
smooth muscle tumor of uncertain malignant 
potential (n = 4), mitotically active leiomyomas 
(n = 2), benign metastasizing leiomyoma (n = 
3), and cotyledonoid dissecting leiomyoma (n = 
1). Thirteen non-smooth muscle tumors that 
involved the uterus were also included, includ-
ing five low grade endometrial stromal sarco-
Table 1. Distribution of scores for each uterine tumor
Tumor No  tested
Distribution of Scores
0 ≥ 1+ 1-5+ 6-9+ 10-12+
Spindle cell leiomyosarcoma 32 0 32 32 25 17
Conventional leiomyoma 30 19 11 10 3 1
Atypical (symplastic) leiomyoma 5 5 0 0 0 0
Cellular leiomyoma 7 7 0 0 0 0
Smooth muscle tumor of uncertain  
malignant potential (STUMP)
4 4 0 0 0 0
Cotyledonoid Dissecting leiomyoma 1 0 0 0 0 1
Benign metastasizing leiomyoma 3 1 2 2 0 0
Mitotically active leiomyoma 2 0 2 2 2 2
Non-smooth muscle sarcomas 13 0 13 3 5 5
Total 97 37 60 20 15 25
alterations in cell division, 
which may eventuate in onco-
genesis [33]. In the gyneco-
logic tract, STMN1 overex-
pression has been identified 
as a negative prognostic fac-
tor in both ovarian and endo-
metrial carcinomas, and may 
have diagnostic utility in cer-
vical and adnexal intraepithe-
lial neoplasias [34-38]. ST- 
MN1 expression has also 
been identified as a signifi-
cant marker of activation of 
the oncogenic phosphati-
dylinositol 3-kinase-AKT-ma- 
mmlian target of rapamycin 
Figure 1. Leiomyosarcoma.
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mas, one Ewing sarcoma, one perivascular epi-
thelioid tumor, one pleomorphic rhabdomyosar-
comas, one embryonal rhabdomyosarcomas, 
one alveolar soft part sarcoma, one dedifferen-
tiated liposarcoma, and one osteosarcoma. 
Immunohistochemistry
Immunohistochemical analyses were perfor- 
med on 1 unstained slide from each case. 
Slides were placed on the Leica Bond Max 
immunohistochemical stainer. All steps besides 
dehydration, clearing and coverslipping are per-
formed on the Bond Max. Slides are deparaf-
finized. Heat induced antigen retrieval was per-
formed on the Bond Max using their Epitope 
Retrieval 2 solution for 20 minutes. The sec-
tions were incubated with a polyclonal antibody 
to STMN1 (Cell Signaling, Danvers, MA; Catalog 
#3352) diluted 1:50 for one hour. The Bond 
Refine Polymer detection system was used for 
visualization. Slides were then dehydrated, 
cleared and coverslipped.
Cases were scored using a system that incorpo-
rated staining intensity (on a 0-3+) scale and 
staining extent (0-4+ scale). These values were 
then multiplied in each case, giving potential 
scores that ranged from 0-12+. All cases were 
scored by 2 authors (MMA and OF). 
Statistics
Subgroups were compared regarding their 
STMN1 staining using the Student t-test (com-
paring mean STMN1 score for each group) or 
Fisher Exact test (comparing STMN1 rates of 
positivity in each group). Odds Ratio, Sensitivity, 
Specificity, Positive Predictive Value, Negative 
Predictive Value for any STMN1 immunoreactiv-
ity in predicting the leiomyosarcoma diagnosis 
were determined using three thresholds for 
positivity (≥ 1+, ≥ 4+, and ≥ 6+) using the vas-
sarstats program (http://www.vassarstats.net/
clin1.html). A p-value of < 0.05 was considered 
statistically significant in all analyses.
Results
The distribution of scores for all tumors is 
reflected in Table 1. The majority of the leio-
myosarcomas were strongly and diffusely posi-
tive for STMN1 expression (Figures 1 and 2), 
whereas most leiomyomata were weakly posi-
tive or negative for STMN1 expression (Figures 
3 and 4). At a ≥ 1+ threshold for positivity, all 
spindle cell leiomyosarcomas were positive 
(32/32 positive; 100%) as compared with con-
ventional leiomyomata (11/30; 37%) (P < 
0.0001). The average score for leiomyosarco-
mas was 8.7 (± 1.43) whereas the conventional 
leiomyomata average score was 1.6 (± 1.07) (P 
< 0.0001). This difference in scores was reflect-
ed in the patterns of expression: leiomyosarco-
mas were predominantly strongly and diffusely 
positive whereas leiomyomata were predomi-
nantly weakly, albeit diffusely positive when 
expression was present (Figure 4). The rate of 
STMN1 positivity in LMS (32/32; 100%) was 
significantly higher than for all other uterine SM 
timors when the latter is considered as a group 
(16/52; 30.8%) (P < 0.0001). All non-smooth 
muscle tumors were positive.
For each threshold for positivity, the sensitivity, 
specificity, positive predictive value, and nega-
tive predictive value of the STMN1 as a bio-
marker for predicting a leiomyosarcoma diag-
nosis among the uterine smooth muscle tumors 
Figure 2. Leiomyosarcoma: diffuse expression of 
STMN1 in leiomyosarcoma. Necrotic areas show de-
creased expression.
Figure 3. Leiomyoma.
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was calculated. We repeated the calculations 
to determine the same parameters for STMN1 
as a biomarker for predicting a leiomyosarco-
ma diagnosis in all uterine tumor cases that 
were included in this study. Table 2 displays 
each test parameter for each threshold for pos-
itivity for the smooth muscle tumors as well as 
all tumors. 
Using a threshold for positivity of ≥ 1+, the sen-
sitivity of the STMN1 expression for leiomyosar-
comas was 100% (95% confidence interval [CI] 
= 87-100%). However, the specificity was found 
to be only 55% (CI = 43-68%). The negative and 
positive predictive values for leiomyosarcomas 
were 100% (CI = 87-100%) and 52% (CI = 
39-65%) respectively. The odds ratio (OR) for 
any STMN1 expression in predicting a spindle 
cell leiomyosarcoma diagnosis from this datas-
et was highly significant (OR = 144, CI = 8-2493, 
P = 0.0006, at the ≥ 1+ threshold), see Table 2.
Discussion
The histologic classification of uterine smooth 
muscle tumors regarding their malignant poten-
tial may potentially be problematic [12], and a 
wide variety of immunohistochemical markers 
have been assessed as potential diagnostic 
adjuncts in this classification. Included in this 
group are p21, p27, p53, p16, IMP3, pan-Akt, 
Ki-67, progesterone receptor, and fascin [10, 
Figure 4. Leiomyoma with foci of no STMN1 expression (left image) and weak STMN1 expression (right image).
Table 2. Test parameters calculated for each threshold for positivity for smooth muscle tumors and all 
tumors included in this study
Threshold for positivity
Parameter ≥ 1+ (95% CI) ≥ 4+ (95% CI) ≥ 6+ (95% CI)
Smooth Muscle Tumors
Odds Ratio 144 (8-2493, P = 0.0006) 17 (6-51, P < 0.0001) 33 (9-114, P < 0.0001)
Sensitivity 100 (87-100) 78 (59-90) 78 (60-90)
Specificity 69 (55-81) 83 (69-91) 90 (77-96)
Positive Predictive Value 67 (51-79) 73 (55-86) 83 (65-97)
Negative Predictive Value 100 (87-100) 86 (73-94) 87 (74-94)
All Tumors
Odds Ratio 80 (4-1370, P = 0.0024) 8.6 (3-23, P < 0.0001) 11 (4-30, P < 0.0001)
Sensitivity 100 (87-100) 78.1 (60-90) 78.1 (60-90)
Specificity 55.4 (43-68) 70.8 (58-81) 75.4 (63-85)
Positive Predictive Value 52.5 (39-65) 56.8 (41-71) 61 (45-75)
Negative Predictive Value 100 (87-100) 86.8 (74-94) 87.5 (75-94)
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16-26, 45]. These markers often have a spe-
cific drawback that limits their utility. For exam-
ple, IMP3 is highly specific for leiomyosarcomas 
but is only moderately sensitive (52% of the 
leiomyosarcomas were positive, 4.2% of the 
leiomyomata variants-cellular or symplastic-
were positive, all conventional leiomyomata 
were negative) [16]. Cell cycle regulatory pro-
tein expression (such as p16, p21, p27, and 
p53) is often distinctly heterogeneous in 
smooth muscle tumors and each cannot be 
depended upon as a sole discriminator between 
benign and malignant smooth muscle prolifera-
tions [10]. Composite profiles tend to be more 
useful. For example, Lee et al reported that dif-
fuse expression of p16 and p53 and/or a high 
Ki-67 proliferation index, yielded a sensitivity of 
92% and a specificity of 98% for separating 
leiomyosarcomas from leiomyomata [20]. 
Fascin and Pan-AKT also show some potential 
diagnostic utility, in that most leiomyosarco-
mas have been found to be positive and most 
leiomyomata negative, but data are limited and 
these markers have not been evaluated in mul-
tiple laboratories [17, 18]. 
The PI3K-AKT-mTOR pathway appears to be 
centrally associated with smooth muscle prolif-
eration and neoplasia in the uterus. In animal 
models, mTOR has been shown to mediate hor-
mone-initiated myometrial hyperplasia in preg-
nancy [42], and both mTOR and phosphati-
dylinositol-3 kinase have been reported to be 
requirements for estrogen-induced prolifera-
tion in cell lines derived from uterine leiomyo-
ma and normal myometrium [43]. Mice carrying 
homologous deletions in an endogenous nega-
tive regulator of the P13K-Akt-mTOR pathway 
developed a variety of benign smooth muscle 
proliferations as well as rapid onset abdominal 
leiomyosarcomas [27]. Although none of the 
resultant malignancies were uterine, this study 
was noteworthy because constitutive activa-
tion of the P13K-Akt-mTOR pathway was only 
found in the leiomyosarcomas, and not the 
benign proliferations, suggesting that PI3K-
AKT-mTOR pathway activation was a necessary 
but insufficient event to develop smooth mus-
cle malignancy [27]. The entire PI3K-AKT-mTOR 
pathway is clearly upregulated in human 
smooth muscle tumors as assessed by gene 
expression profiling [44], and constitutive acti-
vation of the mTORC2-phospholipase D1 path-
way has been demonstrated in uterine leiomyo-
sarcoma (phospholipase D may be an activator 
of mTOR signaling) [31]. Since STMN1 expres-
sion has also been identified as a significant 
marker of activation of the PI3K-AKT-mTOR 
pathway [36-40], we explored how well STMN1 
expression correlated with histologic classifica-
tions of uterine smooth muscle tumors into 
benign and malignant groupings. The ultimate 
goal of this study was to explore the diagnostic 
utility of this marker by establishing its baseline 
performance in non-problematic cases. 
We report that STMN1 is a highly sensitive 
marker for leiomyosarcoma but is suboptimally 
specific for diagnostic purposes. It is not a spe-
cific marker of malignancy within the smooth 
muscle group since 37% of leiomyomata sho- 
wed some STMN1 expression. It is also not a 
specific marker of smooth muscle neoplasia 
since non-smooth muscle sarcomas are fre-
quently positive. The 100% negative predictive 
value for leiomyosarcoma may offer some diag-
nostic utility in a small sample, in that the 
absence of STMN1 immunoreactivity in a puta-
tive leiomyosarcoma is a strong argument 
against the diagnosis. However, this marker 
should be combined with other markers if 
applied even for this purpose. Irrespective of 
whether STMN1 can be applied for diagnostic 
purposes, the patterns of expression may pro-
vide valuable insights into the elusive patho-
genesis of leiomyosarcomas. For example, 5 of 
5 atypical leiomyomas in our dataset were 
STMN1 negative, indicating that STMN1 expres-
sion is not a surrogate indicator for cytologic 
atypia and suggesting a lack of PI3K-AKT-mTOR 
pathway activation in this morphologically dis-
tinct but biologically benign variant; in contrast, 
2 of 2 mitotically active leiomyomata were posi-
tive. Since PI3K-AKT-mTOR play such a central 
role in leiomyosarcomagenesis, STMN1 expres-
sion may provide insights into the primary driv-
ers of this process, and/or their morphologic 
correlates.
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